DNA甲基转移酶抑制剂暴露-反应:挑战和机遇
Amanda B Kagan1,2, Dominique A Garrison2, Nicole M Anders1,3
1Department of Oncology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Clinical and translational science
|June 22, 2023
概括
像阿扎西提丁这样的DNA甲基转移酶抑制剂 (DNMTis) 对于治疗骨髓质疏松综合征和急性骨髓性白血病至关重要. 需要新的生物标志物来预测患者对这些疗法的反应.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- DNA甲基转移酶抑制剂 (DNMTis),包括阿扎西提丁和迪西他,是治疗骨髓显形综合征 (MDS) 和急性髓性白血病 (AML) 的标准治疗方法.
- 尽管它们是有效的,但对DNMT的确切作用机制和临床反应的可靠预测因素仍然不完全理解.
- 确定生物标志物来预测患者的反应是一个至关重要的未满足的需求,因为由于评估临床益处所需的时间,治疗决策往往会被推迟.
研究的目的:
- 审查临床研究和现实世界的数据,支持使用阿扎西蒂丁和德西.
- 探索生物标志物的发展,以预测患者对DNMT的反应.
- 突出技术的进步,以促进药物整合和甲基化水平的测量.
主要方法:
- 总结了关键的临床试验和真实世界的证据,对阿扎西蒂丁和德西.
- 审查当前关于暴露-反应关系和生物标志物挑战的研究.
- 突出了液态染色学双重质谱法 (LC-MS/MS) 的应用,用于同时测量药物基因组合并和全球DNA甲基化.
主要成果:
- 阿扎西提丁和德西在MDS和AML治疗中已经确立了作用,得到了广泛的临床和现实世界的数据的支持.
- 使用先进的LC-MS/MS同时测量decitabine基因组合和全球DNA甲基化,显示其作为一种作用机制生物标志物具有前途.
- 这种新的方法为DNMTi治疗提供了更个性化的方法.
结论:
- 进一步的研究和临床验证对于优化DNMTis的新生物标志物至关重要.
- 开发可靠的生物标志物将能够更好地预测MDS和AML患者的治疗反应.
- 优化生物标志物使用可以改善血液恶性瘤的治疗策略和患者结果.
更多相关视频
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
10.6K
06:43A Quantitative Assay to Study Protein:DNA Interactions, Discover Transcriptional Regulators of Gene Expression, and Identify Novel Anti-tumor Agents
Published on: August 31, 2013
18.8K
相关概念视频
01:38Nucleotide Excision Repair
3.6K
DNA Distortion and Damage
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
3.6K
01:25Mutagenicity and Carcinogenicity
1.3K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.3K